Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(PAZOPanib)
1,632 results
  • S100A10 is a critical mediator of GAS6/AXL-induced angiogenesis in renal cell carcinoma. [Journal Article]
    Cancer Res 2019Xiao Y, Zhao H, … Rankin EB
  • Angiogenesis is a hallmark of cancer that promotes tumor progression and metastasis. However, antiangiogenic agents have limited efficacy in cancer therapy due to the development of resistance. In clear cell renal cell carcinoma (ccRCC), AXL expression is associated with antiangiogenic resistance and poor survival. Here, we establish a role for GAS6/AXL signaling in promoting the angiogenic poten…
  • The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review. [Review]
    Clin Genitourin Cancer 2019Sneed GT, Lee S, … Hammond JM
  • Pazopanib is a protein tyrosine kinase inhibitor that limits tumor growth through angiogenesis inhibition. The use of other protein tyrosine kinase inhibitors, specifically sunitinib, within non-clear cell renal cell carcinoma (nccRCC) has led to increased survival with a decreased adverse event profile. The data for the treatment of nccRCC is limited, with most studies evaluating the use of suni…
New Search Next